Syndax Pharmaceuticals (SNDX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

16.110
+0.280+1.77%

Close Nov 18 16:00 ET

1.38BMarket Cap-4425P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Syndax Pharmaceuticals (SNDX) Gets a Buy From Barclays
TipRanks51minutes ago · Ratings
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $51
Moomoo News03:36 ET · Ratings
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
Moomoo News03:36 ET · Ratings
Syndax Pharmaceuticals' Promising Outlook: Revumenib Approval and Market Potential Justify Buy Rating
TipRanks02:26 ET · Ratings
Express News | Syndax Pharmaceuticals Shares Rise 4.2% After FDA Approves Co's Blood Cancer Drug
ReutersNov 18 10:55 ET
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
BenzingaNov 18 10:07 ET

Comments

Yesterday 03:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

2

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

2

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

2

6

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

3

2

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· just
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation

2

2

Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall

No Data